Drug Trial Radar · NCT07861386
Emulation of the MAVERICC Trial Using Specialty Oncology Electronic Health Records Databases
Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
9,978
Actual
Start
Aug 20, 2026
Primary completion
Aug 20, 2027
Study completion Aug 20, 2027
Sponsor
- Lead sponsor
- Brigham and Women's HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Food and Drug Administration (FDA)
- First posted
- Oct 6, 2026
Design
- Study type
- Observational
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial emulation study aims to emulate the MAVERICC trial (NCT01374425) using real-world specialty oncology electronic health record data and to investigate the concordance between the trial's original and emulated treatment effect estimates on overall survival (OS). MAVERICC was a Phase II, open-label, randomized study assessing the efficacy and safety of modified leucovorin/5-fluorouracil/ oxaliplatin plus bevacizumab (mFOLFOX6-BV) with leucovorin/5-fluorouracil/irinotecan plus bevacizumab (FOLFIRI-BV) in patients with previously untreated metastatic colorectal cancer (mCRC).
Conditions
- Metastatic Colorectal Cancer (mCRC)
Interventions
FOLFIRI plus bevacizumabDrug
Observed initiation of first-line FOLFIRI (leucovorin, fluorouracil, and irinotecan) plus bevacizumab for metastatic colorectal cancer in routine care. Treatment was not assigned by this observational study.
mFOLFOX6 plus bevacizumabDrug
Observed initiation of first-line mFOLFOX6 (modified leucovorin, fluorouracil, and oxaliplatin) plus bevacizumab for metastatic colorectal cancer in routine care. Treatment was not assigned by this observational study.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to all-cause mortality (overall survival)Time frame: From time of initiation of therapy through the earliest of death from any cause (the primary outcome of interest) or end of data availability (depending on the oncology registry data provider; end of data ranges from September 2023 to February 2026)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Brigham and Women's Hospital
Somerville, Massachusetts
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.